New technique shows promise for heart muscle regeneration

Researchers at Duke-NUS Medical School, Singapore, have developed an approach to regenerate heart muscle using stem cells. Their method for priming stem cells to become heart tissues could potentially enable heart regeneration stem cell therapies, according to their study published in the journal Cell Reports. (1)

The self-regeneration of human heart muscle following injury is extremely limited. Scientists have been studying techniques to prompt different kinds of stem cells to differentiate into heart cell precursors, which could then help rebuild heart muscle fibres. However, their approaches have not yet met regulations set forth by the US Food and Drug Administration and the European Medicines Agency for regenerative therapies.

Dr Lynn Yap, a Senior Research Fellow at Duke-NUS’ Cardiovascular and Metabolic Disorders (CVMD) Programme and the study's first author, explained, "Regulatory authorities specifically require these stem-cell-derived precursors be prepared from human-only cells and in cultures that use clearly defined chemicals and no animal components. The method must be reproducible, and the cells must have clear characteristics while not leading to adverse side effects when injected."

Led by senior author, Professor Karl Tryggvason, Tanoto Foundation Professor in Diabetes Research at Duke-NUS' CVMD Programme, the team comprising scientists from Singapore, the UK, Sweden, and the Netherlands investigated using a heart muscle associated protein called laminin for promoting the differentiation of human embryonic stem cells into heart cell precursors.

Laminins attach to the outer parts of cell membranes and are thought to play a role in the differentiation of precursor cells into other types of cells. Several types of laminins exist.

Prof Tryggvason and his team produced laminin-221 in the laboratory by stimulating the human genes that code for this protein. Laminin-221 was then used to coat a culture of pluripotent human embryonic stem cells. They also used laminin-521 to support the growth of the stem cells, and organic compounds called CHIR99021 to boost stem cell differentiation.

Their method led to stem cells differentiating into cardiovascular precursor cells. These included three main sub-populations: cardiac muscle-like cells, fibroblast-like cells, and epithelial-like cells; but did not include cells with a propensity to develop into tumours.

The team was able to reproduce their method with very similar results using two stem cell lines generated decades apart by two different laboratories using different techniques.

Using an animal model, the researchers injected 9- and 11-day-old cardiovascular precursor cells into damaged heart tissue and found these precursor cells differentiated into cardiac muscle fibre bundles that survived in the heart for at least 12 weeks; heart functions also improved.

"These results suggest a role for the use of laminins in cardiac muscle cell differentiation, and may lead the development of clinical-quality cardiovascular progenitor cells for regenerative cardiology in humans," said Prof Tryggvason.

Future research will need to investigate the cell subpopulations that form with this technique to explore whether they can intensify new heart muscle growth in living animals.

Senior Vice Dean for Research at Duke-NUS Medical School, Prof Patrick Casey, commented, "This study is timely as leading experts in heart muscle regeneration have called for a 'sciencedriven path forward'(2) in the field, and the innovative research conducted by Prof Trygvasson and his team delivers an advance that could provide a path forward in this promising new area of cardiovascular therapy."

About Duke-NUS Medical School

Duke-NUS is a partnership between Duke University School of Medicine and the National University of Singapore (NUS).

In 2005, with support from the Singapore government, NUS and Duke University, two academic institutions with strong track records in research and education, committed to combine the unique medical education curriculum at Duke University School of Medicine with the academic rigour and rich resources offered by NUS, and to offer students an enriching and innovative medical educational experience.

Duke-NUS is located on the main campus of the largest healthcare group in the country, Singapore Health Services (SingHealth). This group collectively delivers multi-disciplinary care among 42 clinical specialties across a large network of hospitals, national specialty centres and polyclinics. Together, Duke-NUS and SingHealth constitute a leading, world class Academic Medical Centre embodying the goal of delivering the highest levels of patient care, education and research.

1. Yap L, Wang JW, Moreno-Moral A, Chong LY, Sun Y, Harmston N, Wang X, Chong SY, Ohman MK, Wei H, Bunte R, Gosh S, Cook S, Hovatta O, de Kleijn DPV, Petretto E, Tryggvason K (2019).
In Vivo Generation of Post-infarct Human Cardiac Muscle by Laminin-Promoted Cardiovascular Progenitors.
Cell Reports (March 2019) 26:12;3231-3245. doi: 10.1016/j.celrep.2019.02.083

2. Chien KR, Frisén J, Fritsche-Danielson R, Melton DA, Murry CE and Weissman IL (2019).
Regenerating the field of cardiovascular cell therapy.
Nature Biotechnology 37;232-237. doi: 10.1038/s41587-019-0042-1

Most Popular Now

Study finds lack of racial diversity in cancer dru…

New research published in JAMA Oncology has found a lack of racial and ethnic diversity in clinical trials for cancer drugs. The study - conducted by researchers from UBC...

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Roche's first FDA-approved tumour-agnostic medicin…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek™ (entrectinib) for the treatment of adults with R...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

Amgen and Allergan announce positive top-line resu…

Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...